Drug intelligence / Profile preview

ACAM1000

Development stage: Discontinued
Lead developer: Sanofi Pasteur
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Percutaneous

Overview

ACAM1000 is a live attenuated smallpox vaccine derived from a clone of Dryvax (the first-generation smallpox vaccine). It was developed using modern cell culture technology and grown in African Green Monkey kidney (Vero) cells. The vaccine was designed to provide immunization against smallpox while potentially offering an improved safety profile compared to Dryvax. In clinical trials, ACAM1000 demonstrated 100% take rates and high seroconversion rates, with immunogenicity and safety profiles comparable to Dryvax.

Beyond the preview

Go deeper on ACAM1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACAM1000.

Explore the full profile